Printer Friendly

13 Abstracts on Isomers of Beta-Agonists to Be Presented at ATS Conference.

MARLBOROUGH, Mass., May 18 /PRNewswire/ --

Sepracor Inc. (Nasdaq: SEPR) today announced that 13 abstracts will be presented by university investigators and industry researchers at the American Thoracic Society (ATS) 2001 International Conference in San Francisco, Calif., which runs May 18-23, 2001. At the conference, the following abstracts will be presented:

-- Levalbuterol Improves Pharmacoeconomic Endpoints in Hospitalized Patients. T. Truitt, J. Witko. Halifax Hospital, S. Boston, VA; M. Halpern. Charles River Associates, Washington, D.C.;

-- Levalbuterol is Effective in Acute Asthma. R.M. Nowak. Henry Ford Hospital, Detroit, MI; C.L. Emerman. Cleveland Clinic, Cleveland, OH;

-- Effect of B2 Receptor Agonists on Neurogenic Inflammation in a Rat Model of Respiratory Syncytial Virus Bronchiolitis. K. Wedde-Beer, C. Hu, G. Napchan and G. Piedimonte. Department of Pediatrics, University of Miami School of Medicine, Miami, FL;

-- Effects of Albuterol Enantiomers on Ovine Ciliary Beat Frequency. J. Frohock and M. Salathe. Division of Pulmonary and Crit. Care Med., University of Miami School of Medicine, Miami, FL;

-- (S)-Albuterol or (S,S)-Formoterol Augments IL-4 Production in Mast Cells or Airways of Murine Asthma. Chad K. Oh, M.D., Daniel Abraha, Seong H. Cho. Harbor-UCLA Medical Center, Torrance, CA;

-- GM-CSF Production by Human Airway Smooth Muscle Cells Treated with (R)- and (S)-Enantiomers of Albuterol. B.T. Ameredes, K.L. Hershman, D. Brown, B. Dixon-McCarthy, and W.J. Calhoun. Asthma, Allergy, and Airway Research Center, Div. of Pulmonary, Allergy, and Critical Care Med., Univ. of Pittsburgh School of Med., Pittsburgh, PA;

-- (S)-Albuterol, But Not Other B2-Agonist Isomers, Has Stimulatory Effects on Mucin Secretion and Changes in Gene Expression on Airway Epithelium. Mary M.J. Chang(1), Yu Hua Zhao(1), Yin Chen(1), Jody Hack(1), Mary Ellen Snider(2), Konan Peck(3), and Reen Wu(1). (1) Center for Comparative Respiratory Biology and Medicine, Univ. of California at Davis, CA; (2) Sepracor Inc., Marlborough, MA; (3) Institute of Biomedical Sciences, Academia Sinica, Taiwan;

-- Regulation of Extracellular Matrix Components by Beta-Agonist Enantiomers: A Possible Role for Airway Remodeling. K.M. Hershman, C.M. Neely, B.T. Ameredes, and W.J. Calhoun. AAARC and Div. of Pulmonary, Allergy, & Critical Care Med. Univ. of Pittsburgh, Pittsburgh, PA;

-- Effects of Enantiomers of Beta-Agonists on TNF and IL-10 Release by Human Peripheral Blood Mononuclear Cells [PBMC]. W.J. Calhoun, B. Dixon- McCarthy, C. Neely, K.M. Hershman, J. McClelland, R. Wade, B.T. Ameredes. AAARC, Pulmonary, Allergy, and CCM, University of Pittsburgh, Pittsburgh, PA;

-- Aerosolized Beta-2 Agonists Achieve Therapeutic Levels in the Pulmonary Edema Fluid of Ventilated Patients. K. Atabai, L.B. Ware, M. Snider, P. Koch, B. Daniel, T. Nuckton, M.A. Matthay. Univ. of Calif., CVRI, San Francisco, CA;

-- Attenuation of Inflammation-Induced Changes in Human Neutrophils by Albuterol is Isomeric Specific. C.B. Cairns, C. Hamiel, R.J.P. Musters, C.C. Silliman, A. Banerjee. Colorado Emergency Medicine Research Center, University of Colorado Health Sciences Center, Belle Bonfils Blood Center, Denver, CO;

-- High Efficacy of (R,R)-Formoterol in B2-Adrenoceptor Internalization. R.H. Moore, B.J. Knoll, B.F. Dickey. Baylor College of Medicine & Houston VAMC, Houston, TX;

-- Protective Effect of (R,R)-Formoterol in Early and Late Allergic Response and Airway Hyperresponsiveness in a Mouse Model of Asthma. Devendra K. Agrawal. Center for Allergy, Asthma & Immunology, Creighton Univ. School of Medicine, Omaha, NE.

XOPENEX(R) (levalbuterol HCl) Inhalation Solution

XOPENEX, Sepracor's first self-developed and self-marketed product, continues to gain market share in the unit-dose vial beta-agonist market. At the end of the first quarter 2001, XOPENEX market share for total prescriptions in the unit-dose vial market increased to 16.6 percent. A Supplemental New Drug Application (sNDA) seeking clearance to market XOPENEX inhalation solution at lower dosage strengths for the treatment or prevention of bronchospasm in patients 4 to 11 years old was submitted to the U.S. Food and Drug Administration (FDA) in the first quarter of 2001.

Results of a large-scale (n=340), randomized, double-blind, placebo- controlled, parallel-group, pediatric study have been included in the supplemental filing to the FDA.

Sepracor currently has approximately 200 sales representatives that call on pediatricians, pulmonologists, allergists and primary care physicians for XOPENEX inhalation solution, which is indicated for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease, such as asthma.


It is expected that (R,R)-formoterol will soon enter Phase III trials for the treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) and asthma. In Phase II studies, (R,R)-formoterol inhalation solution used once-daily in patients with COPD and asthma, demonstrated a rapid onset of relief coupled with significant improvement in lung function, versus placebo. (R,R)-Formoterol's Phase II results also showed tolerability comparable to other beta-agonists.

Sepracor Inc. is a research-based pharmaceutical company that develops and commercializes proprietary pharmaceutical products for the primary care and specialty markets. Sepracor's drug development program has yielded an extensive portfolio of pharmaceutical candidates that are focused on the treatment of respiratory, urological and gastroenterological, and central nervous system disorders.

This news release contains forward-looking statements that involve risks and uncertainties, including statements with respect to the safety, efficacy, potential benefits, and successful development of the company's pharmaceuticals under development. Among the factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: the submission, acceptance, and approval of NDAs and sNDAs; the results of clinical trials with respect to products under development; the commercial success of Sepracor's products; the ability of the company to attract and retain qualified personnel; the scope of the company's patent protection with respect to such product candidates; the performance of Sepracor's licensees; the availability of sufficient funds to continue research and development efforts; and certain other factors that may affect future operating results and are detailed in the company's periodic reports filed with the Securities and Exchange Commission.

Xopenex is a registered trademark of Sepracor Inc.

To receive a copy of this release or any recent release via fax, call Sepracor's automated news fax line at 1-800-758-5804 ext. 780960 or visit the website at
COPYRIGHT 2001 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:1USA
Date:May 18, 2001
Previous Article:DaisyLift(TM) Gets a Handle on Toilet Germs.
Next Article:CT EXPO Spring 2001 NAMES Nissi's iTeleFusion BEST OF SHOW.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters